Related Experiment Video
Updated: May 8, 2026
10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models.
Javier J Lepe1,2,3, Jennifer D Tran1,3,4, Naomi Lomeli2,3
1Department of Experimental Pathology and Laboratory Medicine, University of California, Irvine, Irvine, California.
Cancer Research Communications
|May 6, 2026
Summary
Targeting MAGMAS (PAM16), a protein overexpressed in glioblastoma (GBM), with the inhibitor BT9 shows promise. Combining BT9 with temozolomide (TMZ) enhances cell death and overcomes TMZ resistance in GBM.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence despite standard treatments like temozolomide (TMZ).
- Mitochondria-associated granulocyte macrophage colony-stimulating factor molecule (MAGMAS, PAM16) is crucial for mitochondrial protein transport and is overexpressed in GBM.
- Effective therapies are needed to overcome GBM resistance and improve patient survival.
Purpose of the Study:
- To investigate the role of MAGMAS in GBM biology.
- To evaluate the efficacy of MAGMAS inhibition, using the small molecule BT9, in TMZ-resistant glioma cells and patient-derived glioma stem-like cells (GSCs).
Main Methods:
- Assessed PAM16 expression in recurrent GBM, chemoresistant cells, and during metabolic switching.
- Investigated the effects of concurrent BT9 and TMZ treatment on various glioma cell lines.
- Examined the impact of MAGMAS knockdown (shPAM16) on TMZ sensitivity in vitro and in vivo using an intracranial xenograft model.
Main Results:
- Elevated PAM16 levels were observed in recurrent GBM, chemoresistant cells, and during metabolic switching.
- Combined BT9 and TMZ treatment significantly increased glioma cell death compared to monotherapy, regardless of TMZ resistance.
- MAGMAS inhibition (shPAM16) sensitized GBM cells to TMZ in vitro and in vivo.
Conclusions:
- MAGMAS is implicated in GBM progression and chemoresistance.
- Targeting MAGMAS with BT9, particularly in combination with TMZ, represents a promising therapeutic strategy for GBM.
- MAGMAS inhibition can overcome TMZ resistance, offering potential for improved long-term outcomes in GBM patients.
